Newsroom | 5000 results

ROCHDALE, United Kingdom--(BUSINESS WIRE)--Astoriom today announced the appointment of Will Edwards, MBA as CEO to support global scale-up of sample management operations....

ST. LOUIS PARK, Minn.--(BUSINESS WIRE)--Enterra Medical, Inc., today introduced Enterra ReliaStim®, a new stimulation lead designed to make Gastric Electrical Stimulation (GES) lead placement more precise, consistent, and efficient. Enterra ReliaStim, designed and manufactured by Enterra Medical, reflects Enterra Medical’s continued investment in shaping the future of GES and is an important advance in the company’s vision to evolve from a single treatment company into a platform of innovative...

SAN FRANCISCO--(BUSINESS WIRE)--Junevity Announces First Peer-reviewed Research Showing Single-Target Repression Can Reprogram Cellular Aging...

SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--GC Therapeutics, Inc. (GCTx), a biotechnology company created to scale and unlock the next generation of cell therapy-based medicines through its TFome™ cellular programming platform, today announced a series of corporate and pipeline updates. GCTx unveiled its initial pipeline programs focused on demyelinating neurological disorders, including multiple sclerosis (MS), and a regenerative cell therapy program for metabolic diseases, including Type 1 Diabetes. B...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the fourth quarter and full year of 2025 on February 18, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time). The link to the live call will be available on...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its fourth quarter and full year 2025 results after the financial markets close on Thursday, February 19, 2026. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its fourth quarter and full year 2025 financial and operating results. A live webcast of the call w...

AUSTIN, Texas--(BUSINESS WIRE)--Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced positive topline results from its randomized, head-to-head Phase 1b JADE clinical study comparing OLN324, a next-generation VEGF/Ang2 bispecific antibody, to faricimab (Vabysmo®), in over 160 patients with diabetic macular edema (DME) or wet (neovascular) age-related macular degeneration (wAMD). OLN324’s up to 60-fold high...

COLUMBIA, Md.--(BUSINESS WIRE)--Welldoc®, a leader in AI-powered cardiometabolic health solutions, today announced the submission of a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its Continuous Glucose Monitor (CGM)-Informed Glucose Prediction Feature. This submission builds on the company's foundation of 11 FDA 510(k) clearances for type 1 and type 2 diabetes capabilities. The software feature predicts glucose values up to 2 hours for individuals with type...

ROCHESTER, Minn.--(BUSINESS WIRE)--INTENT Biologics, a clinical-stage biotechnology company developing first-in-class exosome-based biologic therapies for serious conditions with significant unmet medical need, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for PEP Biologic™ for the treatment of diabetic foot ulcers (DFU) under IND 019567. FDA Fast Track designation is designed to facilitate the development and expedite the review of drugs an...